Please provide your email address to receive an email when new articles are posted on . The approval follows positive results from the TATE trial. A new 10 mg dose will be available to accommodate ...

Depemokimab-ulaa (Exdensur) is approved for severe asthma with an eosinophilic phenotype, offering protection with just two ...

If the FeNO level is not raised, it is recommended that the patient be offered either a Long-Acting Muscarinic Antagonist (LAMA) or a Leukotriene Receptor Antagonist (LTRA) on top of a moderate-dose ...

Exdensur is now the first twice-yearly add-on maintenance therapy approved for use in severe eosinophilic asthma.

Credit: Getty Images The GINA 2024 asthma update includes new guidance on medications, monitoring, treatment goals, remission, cough variant asthma, children, and more. The Global Initiative for ...

UK's health regulator on Monday approved GSK's twice-yearly drug for use as an add-on treatment for asthma in patients aged ...

In the 12 months after starting tezepelumab, patients with severe asthma had fewer exacerbations, a lower cumulative oral ...

Use of inhaled corticosteroids by pregnant mothers with asthma may protect infants against reduced lung function at 4 to 6 weeks of age.

Among seven new medicines recommended for approval by the EMA's human medicine advisory committee at its latest meeting is ...

TARRYTOWN, N.Y. and PARIS, April 7, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Commission (EC) has expanded the marketing ...